Schering announces start of three Phase II clinical trials with anti-cancer compound ZK-EPO
European trials will assess ZK-EPO in non-small cell lung, ovarian and breast cancers
Schering AG announced the start of three phase II studies in Europe evaluating its fully synthetic epothilone, ZK-EPO, for the treatment of several types of cancers such as non-small cell lung cancer, ovarian cancer and breast cancer. The clinical trials will assess ZK-EPO's safety and efficacy in each of these cancer types. ZK-EPO is the only fully synthetic epothilone in clinical development. It is designed to improve efficacy and safety compared to the chemotherapies currently available.
In non-small cell lung cancer, a multi-center study is currently enrolling patients in Germany. The trial is designed to examine the efficacy and safety of ZK-EPO as second-line therapy in patients with advanced disease.
The ovarian cancer trial is a multi-center Phase II study that is being conducted in the United Kingdom. The study is currently enrolling patients with recurrent ovarian cancer.
The breast cancer trial will enroll patients in 24 medical centers in a number of European countries. The first study centers have been initiated in France and Austria. The trial will investigate the efficacy of ZK-EPO in patients with metastatic breast cancer.
Additional studies with ZK-EPO are being planned in the United States and the EU.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.